🔗 Share this article

While the United States undertakes sweeping adjustments to its vaccination recommendations, a particular individual has surfaced unexpectedly: Dr. Tracy Beth Høeg, a Danish American physician and epidemiologist who initially gained attention by casting doubt on coronavirus shots during the pandemic and has concentrated on potential fatalities after Covid immunization in her short position at the FDA.

Planned Overhauls to Childhood Vaccine Program

Public health authorities planned to announce sweeping changes to the childhood vaccination calendar recently, synchronizing the US with the Danish immunization schedule, sources say – a major change that would place the US at odds with a large portion of the global community with no evidence for benefit. The announcement has been delayed until the coming year.

Instead of the director of the vaccine center, Høeg is listed to present at the meeting. She was newly appointed interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to lead the office this year.

A New Direction at the Regulatory Body

Høeg's temporary position might represent a strengthened alliance between the drug and biologics centers as Dr. Høeg and Dr. Prasad solidify control at the agency – and it signals a increased emphasis upon dismantling previously authorized immunizations at the FDA.

The new acting director has often pushed for halting specific childhood shot schedules in the US to become more like the Danish model, a country with universal health coverage and a citizenry about the population of the state of Wisconsin.

In her initial public appearances, she has kept her attention on immunizations – traditionally the purview of Prasad, director of the FDA’s CBER – rather than drug regulation.

Questions Over Background

Dr. Høeg has no apparent background in drug development, regulation or leadership, which has been customary for previous directors of the CBER. She has been employed at the FDA as a senior adviser to the agency head and the vaccine center since March.

“She doesn’t seem to have any of the qualifications” for overseeing the pharmaceutical oversight division, remarked Dr. Jonathan Howard. “She has not conducted a scientific study. She lacks experience in running a large organization. She is not an expert in drug approvals.”

Past heads of CBER would “be deeply familiar with regulatory frameworks and the research of medication creation”, said a former acting FDA commissioner. “Objectively, she lacks the kind of background that prior appointees who ran the center have had.”

The drug center has an vast portfolio at the FDA, Woodcock pointed out.

“Everybody just pays attention on the new drug program, but the off-patent medication office authorizes thousands of generic drugs. There is also a biologic copycat branch, over-the-counter program and so forth, and all of those need to be managed,” she explained. “The thing you overlook, that is precisely what that I always told people is going to cause problems.”

Furthermore, a major management element to the position, which manages in excess of 5,000 staff members. “It’s a massive management job, if you do it right,” she concluded.

Agency Reaction and Contentious Programs

In response to inquiries about Dr. Høeg's credentials and whether this selection signifies increased cooperation among regulatory chiefs on immunizations, a representative stated that the “inquiries are based on flawed premises”.

“This background aligns with the functions of her position,” the representative stated, citing the period Høeg spent guiding the FDA commissioner on “pharmaceutical safety and oversight research, including computational safety modeling and shot safety tracking”.

As acting director, Høeg assumes responsibility for the agency head's controversial priority voucher program, a contentious one-day medication authorization process that apparently concerned her preceding directors. “How are these medications being chosen for this voucher program? Who makes the decisions?” Dr. Howard asked. “There is a lot of secrecy occurring at the regulatory body right now.”

Overall, he remarked, “the Food and Drug Administration seems to be moving towards laxer regulations of pharmaceuticals, with the exception of shots.”

Documented Past Work on Vaccines

With immunizations, Dr. Høeg has a more established, if problematic, history, Howard have noted. She released a research paper using non-validated volunteer-provided data to determine the incidence of myocarditis following COVID-19 vaccination. She counseled the Florida surgeon general Joseph Ladapo, who allegedly have modified findings to imply COVID-19 vaccinations are more dangerous than they are.

Included in her “desired changes” for the new federal leadership featured altering regulations for novel immunizations and ending “non-essential” immunizations, she remarked following the vote on a online show. At the agency, Dr. Høeg has allegedly suggested preventing teenage boys from getting COVID-19 vaccines.

“She is an complete dogmatist who begins with her conclusions and tailors the evidence to accommodate the data in a extremely misleading, dishonest way,” Howard argued.

Taking Control and a “Push for Payback”

Høeg became part of other contrarians, {like|